Mesoblast Ltd. (NASDAQ:MESO) shares were down 1.2% on Monday . The stock traded as low as $6.06 and last traded at $6.46, with a volume of 54,855 shares trading hands. The stock had previously closed at $6.54.

Several research analysts recently weighed in on MESO shares. Maxim Group reissued a “buy” rating and issued a $14.00 target price (down previously from $18.00) on shares of Mesoblast in a research note on Tuesday, May 10th. Credit Suisse Group AG cut Mesoblast from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $10.00 to $5.00 in a report on Tuesday, June 14th. Finally, Zacks Investment Research cut Mesoblast from a “buy” rating to a “sell” rating in a report on Tuesday, May 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $9.10.

The company’s 50 day moving average is $4.36 and its 200-day moving average is $6.61. The firm’s market capitalization is $479.70 million.

Mesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms, which include specialized cells known as mesenchymal lineage adult stem cells (MLCs), to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.